执行摘要 背景：发热性中性粒细胞减少（NF）发生于早期及转移性实体瘤、非白血病性血液癌症及急性白血病患者。其粗死亡率为3%至18%。
适应症：Neutropenic Fever
入组条件
纳入标准
- ≥18 years
- Tympanic temperature ≥38.3ºC within 24 hours before ED registration
- Last chemotherapy or targeted therapy within 6 weeks for any solid tumour, or in any period following therapies against leukaemia, lymphoma, myelodysplastic syndrome, aplastic anaemia, multiple myeloma, or recipient of HSCT.
排除标准
- \- The decision on how far to apply or deviate from a protocol rests with the clinician. Patients would be excluded from follow up if were unable or unwilling to provide informed consent for data access
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。